{
  "objCls" : "Guideline",
  "@id" : "https://www.pharmgkb.org/data/guideline/PA166104992",
  "@context" : "https://www.pharmgkb.org/jsonld/guideline.jsonld",
  "id" : "PA166104992",
  "name" : "Dutch Pharmacogenetics Working Group Guideline for zuclopenthixol and CYP2D6",
  "relatedChemicals" : [ {
    "objCls" : "Chemical",
    "@id" : "https://www.pharmgkb.org/data/chemical/PA452629",
    "@context" : "https://www.pharmgkb.org/jsonld/chemical.jsonld",
    "id" : "PA452629",
    "name" : "zuclopenthixol"
  } ],
  "relatedGenes" : [ {
    "objCls" : "Gene",
    "@id" : "https://www.pharmgkb.org/data/gene/PA128",
    "@context" : "https://www.pharmgkb.org/jsonld/gene.jsonld",
    "id" : "PA128",
    "symbol" : "CYP2D6",
    "name" : "cytochrome P450, family 2, subfamily D, polypeptide 6"
  } ],
  "source" : "DPWG",
  "summaryHtml" : "<p>For CYP2D6 poor and intermediate metabolizers, reduce zuclopenthixol dose or select an alternative drug.  For ultrarapid metabolizers, be alert to low zuclopenthixol plasma concentrations or select an alternative drug.</p>",
  "textHtml" : "<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for zuclopenthixol based on CYP2D6 genotypes [Article:<a href=\"/pmid/21412232\">21412232</a>].  For PM genotypes, they recommend reducing dose by 50% or selecting an alternative drug.  For IM genotypes, they recommend reducing dose by 25% or selecting an alternative drug.  For UM genotypes, they state that there are insufficient data to allow calculation of dose adjustment, and to be alert to low zuclopenthixol plasma concentrations or to select an alternative drug.</p><table class=\"table table-striped table-condensed table-hover table-bordered\"><tr><th> Phenotype (Genotype) </th><th> Therapeutic Dose Recommendation </th><th> Level of Evidence </th><th> Clinical Relevance </th></tr><tr><td> PM (two inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) alleles) </td><td> Reduce dose by 50% or select alternative drug (e.g., flupenthixol, quetiapine, olanzapine, clozapine). </td><td> Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints. </td><td> Minor clinical effect (S): QTc prolongation (&lt;450 ms , &lt;470 ms ); INR increase &lt; 4.5.  Kinetic effect (S).</td></tr><tr><td>IM (two decreased-activity (*9, *10, *17, *29, *36, *41) alleles or carrying one active (*1, *2, *33, *35) and one inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) allele, or carrying one decreased-activity (*9, *10, *17, *29, *36, *41) allele and one inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) allele) </td><td> Reduce dose by 25% or select alternative drug (flupenthixol, quetiapine, olanzapine, clozapine).</td><td> Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints. </td><td>Minor clinical effect (S): QTc prolongation (&lt;450 ms female, &lt;470 ms male); INR increase &lt; 4.5. Kinetic effect (S). </td></tr><tr><td> UM (a gene duplication in absence of inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) or decreased-activity (*9, *10, *17, *29, *36, *41) alleles) </td><td> Insufficient data to allow calculation of dose adjustment. Be alert to low zuclopenthixol plasma concentrations or select alternative drug (flupenthixol, quetiapine, olanzapine, clozapine). </td><td> not given. </td><td> not given. </td></tr></table><ul><li>*See <a href=\"http://www.pharmgkb.org/home/dutch_pharmacogenetics_working_group.jsp\">Methods</a> or <a href=\"http://www.pharmgkb.org/pmid/18253145\">PMID: 18253145</a> for definition of \"good quality.\"</li><li>S: statistically significant difference.</li><li>Please see attached PDF for detailed information about the evaluated studies: <a href=\"/download.do?objCls=Attachment&amp;objId=zuclopenthixol_CYP2D6_271111.pdf\" title=\"link tip\">Zuclopenthixol CYP2D6</a></li></ul>"
}